Covid-19 vaccine, Covaxin, being developed by Bharat Biotech is now undergoing phase-3 trials, Krishna Ella, Chairman and Managing Director, Bharat Biotech said on Monday. Addressing virtually at a programme organized by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year, for which we partnered with ICMR for Covid-19 vaccine as we speak it entered the phase 3 trials.  Bharat Biotech is the only vaccine company in the world that has BSL3 production facility (Biosafety level 3), he added.

Last month the company said it had successfully completed the interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participants. Covaxinis being developed by BharatBiotech, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

The Hyderabad-based vaccine maker had on October 2 sought the Drug Controller General of India's (DCGI) go-ahead to conduct phase 3 randomized double-blind place the bo-controlled multicentre trial of its COVID-19 vaccine, sources said. "We are working on another vaccine through nasal drops my feeling is by next year it will reach the population," Ella said.

'Life will be normal till next year' claims Scientist who made '90% successful vaccine'

Johnson&Johnson starts 2-dose trial of its COVID-19 vaccine

Serum Institute CEO claims India Will Get 100 mn Oxford Vaccine Shots By December